Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Research Report 2021

Hepatitis B is a viral infection caused due to transmission of the virus through contact with the blood or other body fluids of an infected person. It is considered as a serious occupational hazard for healthcare professionals, which affects the liver, causing acute and chronic diseases. Hence, Chinese hamster ovary cell (CHO) hepatitis B vaccine is considered to be the safe and effective method to prevent the hepatitis B infection. The major factor that fuels the growth of the market are increase in prevalence of hepatitis B infection worldwide. For example, approximately 887,000 deaths due to hepatitis B infection were recorded in 2015 across the globe. However, inherent disadvantages of using recombinant Chinese hamster ovary cell (CHO) to design hepatitis B vaccines restrains the growth of the market. Conversely, increase in government focus to promote (CHO) hepatitis B vaccination for adults and extensive research carried out for the same are expected to offer lucrative opportunities for the market.

The global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine market was valued at US$ XX million in 2019 and is expected to reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
This report focuses on Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Pediatric Hepatitis B (CHO) Vaccine
Adult Hepatitis B (CHO) Vaccine

Segment by Application
Hospitals
Clinics

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Merck & Co., Inc.
GlaxoSmithKline Plc
Pfizer Inc.
Sanofi Pasteur
CSL Limited
Emergent Biosolutions
Serum Institute of India
Johnson & Johnson